Literature DB >> 27246772

Minoxidil for Treatment of Resistant Hypertension in Chronic Kidney Disease--A Retrospective Cohort Analysis.

Heiko M Mundt1, Matthias Matenaer2, Alexander Lammert2, Uwe Göttmann3, Bernhard K Krämer2, Rainer Birck2, Urs Benck2.   

Abstract

Resistant hypertension is still a challenge and reserve antihypertensive agents are often necessary to achieve blood pressure control. One reserve antihypertensive is minoxidil, a direct vasodilator that is known for its strong blood pressure-lowering effect, but contemporary studies are sparse. The authors retrospectively analyzed 54 inpatients with uncontrolled hypertension despite the combined use of current antihypertensive agents. To investigate the effect of minoxidil when added to other antihypertensive agents, blood pressure was evaluated at the time minoxidil treatment was initiated and at discharge. Minoxidil treatment was associated with a significant reduction in blood pressure from 162.4±15.1/83.2±12.7 mm Hg to 135.8±12.2/72.8±6.9 mm Hg (P<.0001). This effect was sustained across all analyzed subgroups. Although the well-known adverse events of minoxidil limit its widespread use, these data show that minoxidil as a reserve antihypertensive agent still has a niche indication in the particular subgroup of patients with treatment-resistant or uncontrolled hypertension. ©2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27246772      PMCID: PMC8031757          DOI: 10.1111/jch.12847

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  51 in total

Review 1.  Resistant hypertension: diagnosis and management.

Authors:  Dimitris P Papadopoulos; Vasilios Papademetriou
Journal:  J Cardiovasc Pharmacol Ther       Date:  2006-06       Impact factor: 2.457

2.  Minoxidil in resistant hypertension.

Authors:  H J Dargie; C T Dollery; J Daniel
Journal:  Lancet       Date:  1977-09-10       Impact factor: 79.321

3.  Clinical experience of long-term treatment with minoxidil in severe arterial hypertension.

Authors:  K E Hagstam; R Lundgren; J Wieslander
Journal:  Scand J Urol Nephrol       Date:  1982

4.  Long-term effects of minoxidil therapy on renal function of patients with refractory hypertension: the significance of albuminuria.

Authors:  T Kern; V DeQuattro; J F Bornheimer; E DeQuattro; R E Kolloch
Journal:  J Cardiovasc Pharmacol       Date:  1980       Impact factor: 3.105

5.  Felodipine can replace minoxidil in the treatment of refractory hypertension.

Authors:  D MacLeod; C G Wathen; L Tucker; E A Forret; T W Hill; A L Muir
Journal:  J Hypertens Suppl       Date:  1985-12

Review 6.  Direct-acting vasodilators.

Authors:  Jay N Cohn; Gordon T McInnes; Alexander M Shepherd
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-07-18       Impact factor: 3.738

Review 7.  Drug therapy for resistant hypertension: simplifying the approach.

Authors:  Samuel J Mann
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-11-08       Impact factor: 3.738

Review 8.  Minoxidil: an underused vasodilator for resistant or severe hypertension.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-05       Impact factor: 3.738

9.  2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad; Josep Redon; Anna Dominiczak; Krzysztof Narkiewicz; Peter M Nilsson; Michel Burnier; Margus Viigimaa; Ettore Ambrosioni; Mark Caufield; Antonio Coca; Michael Hecht Olsen; Roland E Schmieder; Costas Tsioufis; Philippe van de Borne; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Denis L Clement; Antonio Coca; Thierry C Gillebert; Michal Tendera; Enrico Agabiti Rosei; Ettore Ambrosioni; Stefan D Anker; Johann Bauersachs; Jana Brguljan Hitij; Mark Caulfield; Marc De Buyzere; Sabina De Geest; Geneviève Anne Derumeaux; Serap Erdine; Csaba Farsang; Christian Funck-Brentano; Vjekoslav Gerc; Giuseppe Germano; Stephan Gielen; Herman Haller; Arno W Hoes; Jens Jordan; Thomas Kahan; Michel Komajda; Dragan Lovic; Heiko Mahrholdt; Michael Hecht Olsen; Jan Ostergren; Gianfranco Parati; Joep Perk; Jorge Polonia; Bogdan A Popescu; Zeljko Reiner; Lars Rydén; Yuriy Sirenko; Alice Stanton; Harry Struijker-Boudier; Costas Tsioufis; Philippe van de Borne; Charalambos Vlachopoulos; Massimo Volpe; David A Wood
Journal:  Eur Heart J       Date:  2013-06-14       Impact factor: 29.983

Review 10.  Management of patients with resistant hypertension: current treatment options.

Authors:  Nilay Kumar; David A Calhoun; Tanja Dudenbostel
Journal:  Integr Blood Press Control       Date:  2013-10-22
View more
  4 in total

Review 1.  Resistant Hypertension: Mechanisms and Treatment.

Authors:  Andrew Y Hwang; Eric Dietrich; Carl J Pepine; Steven M Smith
Journal:  Curr Hypertens Rep       Date:  2017-07       Impact factor: 5.369

Review 2.  Treatment of Hypertension in Chronic Kidney Disease.

Authors:  Rigas G Kalaitzidis; Moses S Elisaf
Journal:  Curr Hypertens Rep       Date:  2018-06-11       Impact factor: 5.369

3.  Minoxidil for Treatment of Resistant Hypertension in Chronic Kidney Disease--A Retrospective Cohort Analysis.

Authors:  Heiko M Mundt; Matthias Matenaer; Alexander Lammert; Uwe Göttmann; Bernhard K Krämer; Rainer Birck; Urs Benck
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-06-01       Impact factor: 3.738

Review 4.  Towards the Development of AgoKirs: New Pharmacological Activators to Study Kir2.x Channel and Target Cardiac Disease.

Authors:  Laura van der Schoor; Emma J van Hattum; Sophie M de Wilde; Netanja I Harlianto; Aart-Jan van Weert; Meye Bloothooft; Marcel A G van der Heyden
Journal:  Int J Mol Sci       Date:  2020-08-11       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.